Bristol Myers Squibb Ends Breyanzi Manufacturing Deal With Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand the manufacturing of Breyanzi, a personalized blood cancer therapy. A company spokesperson stated that the Cellares manufacturing platform, known as Cell Shuttle, failed to meet the requirements for producing the CAR-T therapy at a commercial scale.

The 2024 agreement was valued at up to $380 million and provided reserved manufacturing capacity across the United States, the European Union, and Japan. Breyanzi, used to treat lymphoma and other blood cancers, generated $1.36 billion in sales in 2025.

Following the loss of the contract, Cellares CEO Fabian Gerlinghaus announced that the company will resize its workforce. The company did not provide specific details regarding the number of layoffs.